Close Menu

NEW YORK (GenomeWeb) – Trovagene announced after the close of the market on Wednesday a 14 percent year-over-year drop in fourth quarter revenues. The firm also announced a restructuring program to expand into precision cancer drug development.

The liquid biopsy molecular diagnostics developer said its revenues were $68,000 for the three  months ended Dec. 31, 2016, compared to $79,000 in Q4 2015, and significantly short of the analysts' average estimate of $180,000.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

According to New Scientist, GEDmatch changed its terms and conditions over the weekend to opt its users out of law enforcement searches.

The Atlantic looks into time spent pursuing gene leads generated through candidate gene studies.

A twin study uncovers evidence that genes may influence whether someone gets a dog, Martha Stewart reports.

In PNAS this week: Cdx2 cells can help regenerate heart tissue in mice following a heart attack, PIWI-interacting small RNA levels in human cancer, and more.